Email Us
View Reports

Dyax Corp. Company Profile - Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation

  • ID : 1832851  |  
  • Published : Apr-2018  |  
  • Region : Global  |  
  • Pages : 36   |  
  • Publisher : Market Data Forecast

Dyax Corp. (Dyax or 'the company') is an integrated biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. The company operates in the US predominantly.

The company's lead product, ecallantide has been approved under the brand name Kalbitor in the US for the treatment of acute attacks of HAE in patients 12 years of age and older. Dyax has a commercial organization to support sales of Kalbitor in the US, and establishing strategic collaborations to develop and commercialize ecallantide for the treatment of HAE in key regions worldwide. Currently, Dyax has collaboration agreements for regions including China, Korea, Taiwan, Japan, and select countries in Latin America (including Argentina, Brazil, Chile, Colombia, Mexico and Venezuela), Algeria, Tunisia, Morocco and South Africa.

Dyax is currently developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein to be used as a subcutaneous injection for the prophylactic treatment of HAE in patients. In order to expedite the development of DX-2930, the company has also developed a biomarker assay that detects evidence of plasma kallikrein activity in patient blood.

Dyax identified ecallantide and other compounds using its patented phage display technology. The technology rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the Licensing and Funded Research Portfolio (LFRP). Collectively, LFRP agreements generate significant revenue for Dyax in the form of license fees, milestone payments and/or royalties. The LFRP's advanced licensee pipeline includes one approved product, Cyramza (ramucirumab) which is marketed by Eli Lilly and Company (Lilly) and multiple product candidates in various stages of clinical development.

Scope of the Report

-- About the Company - Historical Details, Current Ownership Structure and basic overview of Dyax Corp. in terms of revenue, net income, and operating income.

-- Financials - Details about Dyax Corp. listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.

-- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.

-- Company SWOT Analysis - Outlines Dyax Corp. ’s strengths, weaknesses, and opportunities and threats facing the company.

-- Recent Developments - Showcases Dyax Corp. ’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.

-- Strategic Evaluation - Provides an overview of Dyax Corp. ’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.

-- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.

Key Questions Answered

-- What domain does Dyax Corp. operate and what are key points about it?

-- What is the product / service portfolio of Dyax Corp. ?

-- How has Dyax Corp. performed financially from the 2013?

-- How does Dyax Corp. rank among its peers in terms of revenue and market share?

-- What are Dyax Corp. strengths and weaknesses and what opportunities and threats does it face?

-- What are Dyax Corp. ’s main growth strategies and how successful has the company been at implementing them?

-- What is the in-house technical capability of Dyax Corp. ? Where does it procure / outsource it?

Reasons to buy

-- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own

-- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost

-- 12 hour delivery time fulfilling your urgent requests as per your requirement

-- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics

1. About the Company

1.1 History and Basic Facts

1.2 Ownership Structure and Key Executives

1.3 Head Office

1.4 Other Locations & Subsidiaries

1.5 List of Competitors

1.6 Employee Count & Distribution

2. Financials

2.1 Company Type (Listed / Unlisted)

2.2 Annual Statements

2.3 Key Financial Highlights

2.4 Region-wise Breakdown

3. Product / Services

3.1 Overview

3.2 Description

4. SWOT Analysis

4.1 SWOT Overview

4.2 Strengths

4.3 Weaknesses

4.4 Opportunities

4.5 Threats

5. Recent Developments

5.1 Mergers & Acquisitions

5.2 Partnerships, Collaborations & Joint Ventures

5.3 New Product Launches

5.4 Business Expansion / Divestment

6. Strategic Evaluation

6.1 Corporate Strategy

6.2 Legal Issues

6.3 Analyst Outlook

7. Technology Landscape

7.1 Industry

-- 7.1.1 Industry Snapshot

-- 7.1.2 IT Spend

-- 7.1.3 Key Information Technology Trends

7.2 Company

-- 7.2.1 IT Overview

-- 7.2.2 Key IT Technologies

-- 7.2.3 Recent IT Initiatives

-- 7.2.4 IT Outsourcing Engagements

-- 7.2.5 Key IT Management

-- 7.2.6 CIO/CTO Profile

Appendix

-- Methodology

-- About Us

-- Contact Us

-- Disclaimer

Fig.1: Company Snapshot

Fig.2: Locations Listing on Map

Table.1: Ownership Structure

Table.2: List of Competitors

Table.3: Annual Statements

Table.4: Key Financial Highlights

Table.5: Region-wise Breakdown

Table.6: Product/Services Overview

Table.7: Mergers & Acquisitions

Table.8: Partnerships, Collaborations & Joint Ventures

Table.9: New Product Launches

Table.10: Business Expansion / Divestment

Table 11: IT Budgets

Table 12: Key IT Management (CIO / CTO)

Table 13: IT Deals undertaken in the past years

Purchase this Market Research Report

REACH OUT TO US

Call us on : +1 888 709 8757

Drop us an email at : info@researchcosmos.com

HAVE A QUESTION?